RESEARCH TRIANGLE PARK, N.C., Feb. 4 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that Gwendolyn Powell Painter, M.D., M.P.H., has joined the company as Chief Medical Officer.
Dr. Painter has more than 20 years of experience in the pharmaceutical industry, including work in clinical development, clinical safety and pharmacovigilance, and occupational and environmental medicine. In her role as Chief Medical Officer, Dr. Painter will be responsible for clinical strategy and development of Chimerix's proprietary antiviral medicines addressing life-threatening diseases. Dr. Painter has been working with Chimerix since 2002 in a consulting capacity, providing medical oversight and clinical consulting.
"We are delighted to have Wendy join our leadership team. Her extensive background in all phases of antiviral drug development has been and will be invaluable as we advance our pipeline through the clinical trials process," said Kenneth I. Moch, Chimerix's Chief Operating Officer. "Wendy has been a vital force in the development of our broad-spectrum antiviral candidate CMX001."
Dr. Painter has an extensive background in drug development at a number of biotechnology and pharmaceutical companies. Her experience includes having served as Medical Director at GlaxoSmithKline (GSK) where she had responsibility for worldwide antiviral clinical safety. While there, she was involved in a number of antiviral Investigational New Drug (IND) applications and New Drug Application (NDA) submissions to the U.S. Food and Drug Administration. Subsequently, she provided expert medical consulting to a range of biotechnology and pharmaceutical companies regarding d
|SOURCE Chimerix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved